How intravitreal anti-vascular endothelial growth factor initial dosing impacts patient outcomes in diabetic macular oedema

How intravitreal anti-vascular endothelial growth factor initial dosing impacts patient outcomes in diabetic macular oedema

Abstract Background Intravitreal anti-vascular endothelial growth factor (VEGF) treatment for diabetic macular oedema (DME) may begin with several initial monthly doses. Characteristics, treatment patterns and outcomes were compared for eyes with DME that did and did not receive such initial doses....

Full description

Saved in:
Bibliographic Details
Main Authors: Rishi P. Singh, David Tabano, Blanche L. Kuo, Andrew LaPrise, Theodore Leng, Eunice Kim, Meghan Hatfield, Vincent Garmo
Format: Article
Language:English
Published: BMC 2024-12-01
Series:BMC Ophthalmology
Subjects:
Diabetic macular oedema
Anti-vascular endothelial growth factor
Intravitreal injections
Loading dose
Online Access:https://doi.org/10.1186/s12886-024-03797-9
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items